547 related articles for article (PubMed ID: 33915626)
1. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
[No Abstract] [Full Text] [Related]
2. Pre-operative nomogram predicting malignant potential in the patients with intraductal papillary mucinous neoplasm of the pancreas: focused on imaging features based on revised international guideline.
Hwang JA; Choi SY; Lee JE; Kim SS; Lee S; Moon JY; Heo NH
Eur Radiol; 2020 Jul; 30(7):3711-3722. PubMed ID: 32095876
[TBL] [Abstract][Full Text] [Related]
3. Importance of each high-risk stigmata and worrisome features as a predictor of high-grade dysplasia in intraductal papillary mucinous neoplasms of the pancreas.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Pancreatology; 2020 Jul; 20(5):895-901. PubMed ID: 32624417
[TBL] [Abstract][Full Text] [Related]
4. A large multicenter study of recurrence after surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas.
Yan L; Siddiqui AA; Laique SN; Saumoy M; Kahaleh M; Yoo J; Kalra A; Mathew A; Sterling J; Rao R; Lieberman M; Cosgrove N; Sharaiha RZ
Minerva Gastroenterol Dietol; 2017 Mar; 63(1):50-54. PubMed ID: 27824244
[TBL] [Abstract][Full Text] [Related]
5. Validation of Indications for Surgery of European Evidence-Based Guidelines for Patients with Pancreatic Intraductal Papillary Mucinous Neoplasms.
Jan IS; Chang MC; Yang CY; Tien YW; Jeng YM; Wu CH; Chen BB; Chang YT
J Gastrointest Surg; 2020 Nov; 24(11):2536-2543. PubMed ID: 31745906
[TBL] [Abstract][Full Text] [Related]
6. An integrated analysis of host- and tumor-derived markers for predicting high-grade dysplasia and associated invasive carcinoma of intraductal papillary mucinous neoplasms of the pancreas.
Hata T; Mizuma M; Motoi F; Ishida M; Morikawa T; Nakagawa K; Hayashi H; Kanno A; Masamune A; Kamei T; Naitoh T; Furukawa T; Unno M
Surg Today; 2020 Sep; 50(9):1039-1048. PubMed ID: 32124086
[TBL] [Abstract][Full Text] [Related]
7. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.
Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR
JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Indications for Limited Surgery of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Kimura K; Amano R; Ymazoe S; Ohira G; Nishio K; Hirakawa K; Ohira M
World J Surg; 2017 May; 41(5):1358-1365. PubMed ID: 27882420
[TBL] [Abstract][Full Text] [Related]
9. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
[TBL] [Abstract][Full Text] [Related]
10. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
[TBL] [Abstract][Full Text] [Related]
11. Carbohydrate Antigen 19-9 Is an Invasive Malignancy Preoperative Prognostic Factor for Intraductal Papillary Mucinous Neoplasms.
Suzuki S; Shimoda M; Shimazaki J; Oshiro Y; Nishda K; Orimoto N; Nagakawa Y; Tsuchida A
Eur Surg Res; 2021; 62(4):262-270. PubMed ID: 34344012
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and Prognostic Impact of Neutrophil-to-Lymphocyte Ratio for Intraductal Papillary Mucinous Neoplasms of the Pancreas With High-Grade Dysplasia and Associated Invasive Carcinoma.
Hata T; Mizuma M; Motoi F; Ishida M; Morikawa T; Takadate T; Nakagawa K; Hayashi H; Kanno A; Masamune A; Kamei T; Furukawa T; Naitoh T; Unno M
Pancreas; 2019 Jan; 48(1):99-106. PubMed ID: 30540681
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic Fluid Interleukin-1β Complements Prostaglandin E2 and Serum Carbohydrate Antigen 19-9 in Prediction of Intraductal Papillary Mucinous Neoplasm Dysplasia.
Simpson RE; Yip-Schneider MT; Flick KF; Wu H; Colgate CL; Schmidt CM
Pancreas; 2019 Sep; 48(8):1026-1031. PubMed ID: 31404023
[TBL] [Abstract][Full Text] [Related]
14. Imaging Features for Predicting High-Grade Dysplasia or Malignancy in Branch Duct Type Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Systematic Review and Meta-Analysis.
Zhao W; Liu S; Cong L; Zhao Y
Ann Surg Oncol; 2022 Feb; 29(2):1297-1312. PubMed ID: 34554343
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic juice cytology as sensitive test for detecting pancreatic malignancy in intraductal papillary mucinous neoplasm of the pancreas without mural nodule.
Kawada N; Uehara H; Nagata S; Tomita Y; Nakamura H
Pancreatology; 2016; 16(5):853-8. PubMed ID: 27459913
[TBL] [Abstract][Full Text] [Related]
16. The validity of the surgical indication for intraductal papillary mucinous neoplasm of the pancreas advocated by the 2017 revised International Association of Pancreatology consensus guidelines.
Watanabe Y; Endo S; Nishihara K; Ueda K; Mine M; Tamiya S; Nakano T; Tanaka M
Surg Today; 2018 Nov; 48(11):1011-1019. PubMed ID: 29961172
[TBL] [Abstract][Full Text] [Related]
17. Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: development of a preoperative nomogram.
Correa-Gallego C; Do R; Lafemina J; Gonen M; D'Angelica MI; DeMatteo RP; Fong Y; Kingham TP; Brennan MF; Jarnagin WR; Allen PJ
Ann Surg Oncol; 2013 Dec; 20(13):4348-55. PubMed ID: 24046103
[TBL] [Abstract][Full Text] [Related]
18. Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm.
Fujita Y; Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Ueno M; Hayami S; Kobayashi R; Yanagisawa A; Yamaue H
Eur J Surg Oncol; 2022 May; 48(5):1054-1061. PubMed ID: 34933794
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic Resection for Side-Branch Intraductal Papillary Mucinous Neoplasm (SB-IPMN): a Contemporary Single-Institution Experience.
Dortch JD; Stauffer JA; Asbun HJ
J Gastrointest Surg; 2015 Sep; 19(9):1603-9. PubMed ID: 26055134
[TBL] [Abstract][Full Text] [Related]
20. Predictive Factors for the Metachronous Development of High-risk Lesions in the Remnant Pancreas After Partial Pancreatectomy for Intraductal Papillary Mucinous Neoplasm.
Miyasaka Y; Ohtsuka T; Tamura K; Mori Y; Shindo K; Yamada D; Takahata S; Ishigami K; Ito T; Tokunaga S; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Ann Surg; 2016 Jun; 263(6):1180-7. PubMed ID: 26334637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
